Precigen Announces FDA Clearance of its Investigational New Drug Application to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients
luke@benzinga.com